Adjuvant treatment of hepatocellular carcinoma after orthotopic liver transplantation: Do we really need this?

Clinical Transplantation

Volumn 27, Issue 2, 2013, Pages 169-177

  Fujiki, M ^a   Aucejo, F ^a   Kim, R ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Adjuvant treatment; Biomarkers; Hepatocellular carcinoma; Orthotopic liver transplantation

Indexed keywords

ANTINEOPLASTIC AGENT; BETA CATENIN; CISPLATIN; DOXORUBICIN; FLUOROURACIL; FOLINIC ACID; LICARTIN; OXALIPLATIN; RAPAMYCIN; SORAFENIB; TACROLIMUS; UNCLASSIFIED DRUG; UVOMORULIN; VASCULOTROPIN;

ADJUVANT THERAPY; ADVANCED CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; DISEASE FREE SURVIVAL; FOLLOW UP; HEPATITIS B; HEPATITIS C; HIGH RISK PATIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; REVIEW;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL MARKERS; CARCINOMA, HEPATOCELLULAR; CHEMOTHERAPY, ADJUVANT; FLUOROURACIL; HUMANS; LEUCOVORIN; LIVER NEOPLASMS; LIVER TRANSPLANTATION; NEOPLASM RECURRENCE, LOCAL; NIACINAMIDE; ORGANOPLATINUM COMPOUNDS; PHENYLUREA COMPOUNDS; TOR SERINE-THREONINE KINASES;

EID: 84876097155     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/ctr.12042     Document Type: Review

References (69)

1. Berg CL, Steffick DE, Edwards EB et al. Liver and intestine transplantation in the United States 1998-2007. Am J Transplant 2009: 9: 907.
2. Lavanchy D. Worldwide epidemiology of HBV infection, disease burden, and vaccine prevention. J Clin Virol 2005: 34(Suppl 1): S1.
3. Marcellin P. Hepatitis B and hepatitis C in 2009. Liver Int. 2009: 29(Suppl 1): 1.
4. Almhanna K, Kalmadi S, Pelley R, Kim R. Neoadjuvant therapy for hepatocellular carcinoma: is there an optimal approach? Oncology (Williston Park) 2007: 21: 1116.
5. Mazzaferro V, Regalia E, Doci R et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996: 334: 693.
6. Roayaie S, Schwartz JD, Sung MW et al. Recurrence of hepatocellular carcinoma after liver transplant: patterns and prognosis. Liver Transpl 2004: 10: 534.
7. Toso C, Trotter J, Wei A et al. Total tumor volume predicts risk of recurrence following liver transplantation in patients with hepatocellular carcinoma. Liver Transpl 2008: 14: 1107.
8. Fujiki M, Takada Y, Ogura Y et al. Significance of des-gamma-carboxy prothrombin in selection criteria for living donor liver transplantation for hepatocellular carcinoma. Am J Transplant 2009: 9: 2362.
9. Yao FY, Ferrell L, Bass NM, Bacchetti P, Ascher NL, Roberts JP. Liver transplantation for hepatocellular carcinoma: comparison of the proposed UCSF criteria with the Milan criteria and the Pittsburgh modified TNM criteria. Liver Transpl 2002: 8: 765.
10. Pichlmayr R, Weimann A, Ringe B. Indications for liver transplantation in hepatobiliary malignancy. Hepatology 1994: 20: 33S.
11. Penn I. Hepatic transplantation for primary and metastatic cancers of the liver. Surgery 1991: 110: 726.
12. Yokoyama I, Todo S, Iwatsuki S, Starzl TE. Liver transplantation in the treatment of primary liver cancer. Hepatogastroenterology 1990: 37: 188.
13. Llovet JM, Ricci S, Mazzaferro V et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008: 359: 378.
14. Cheng AL, Kang YK, Chen Z et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009: 10: 25.
15. Nerenstone SR, Ihde DC, Friedman MA. Clinical trials in primary hepatocellular carcinoma: current status and future directions. Cancer Treat Rev 1988: 15: 1.
16. Di Bisceglie AM, Rustgi VK, Hoofnagle JH, Dusheiko GM, Lotze MT. NIH conference. Hepatocellular carcinoma. Ann Intern Med 1988: 108: 390.
17. Stone MJ, Klintmalm GB, Polter D et al. Neoadjuvant chemotherapy and liver transplantation for hepatocellular carcinoma: a pilot study in 20 patients. Gastroenterology 1993: 104: 196.
18. Roayaie S, Frischer JS, Emre SH et al. Long-term results with multimodal adjuvant therapy and liver transplantation for the treatment of hepatocellular carcinomas larger than 5 centimeters. Ann Surg 2002: 235: 533.
19. Pokorny H, Gnant M, Rasoul-Rockenschaub S et al. Does additional doxorubicin chemotherapy improve outcome in patients with hepatocellular carcinoma treated by liver transplantation? Am J Transplant 2005: 5: 788.
20. Soderdahl G, Backman L, Isoniemi H et al. A prospective, randomized, multi-centre trial of systemic adjuvant chemotherapy versus no additional treatment in liver transplantation for hepatocellular carcinoma. Transpl Int 2006: 19: 288.
21. Zhang Q, Chen H, Li Q et al. Combination adjuvant chemotherapy with oxaliplatin, 5-fluorouracil and leucovorin after liver transplantation for hepatocellular carcinoma: a preliminary open-label study. Invest New Drugs 2011: 29: 1360.
22. Trojan J, Lubomierski N, Lehnert T et al. Neoadjuvant treatment with cetuximab, 5-fluorouracil, folinic acid and oxaliplatin in unresectable retroperitoneal recurrent colon cancer. Z Gastroenterol 2008: 46: 776.
23. Xu J, Zhong Y, Weixin N et al. Preoperative hepatic and regional arterial chemotherapy in the prevention of liver metastasis after colorectal cancer surgery. Ann Surg 2007: 245: 583.
24. Poggi G, Quaretti P, Minoia C et al. Transhepatic arterial chemoembolization with oxaliplatin-eluting microspheres (OEM-TACE) for unresectable hepatic tumors. Anticancer Res 2008: 28: 3835.
25. Li S, Niu Z, Tian H et al. Treatment of advanced hepatocellular carcinoma with gemcitabine plus oxaliplatin. Hepatogastroenterology 2007: 54: 218.
26. Chen ZN, Mi L, Xu J et al. Targeting radioimmunotherapy of hepatocellular carcinoma with iodine (131I) metuximab injection: clinical phase I/II trials. Int J Radiat Oncol Biol Phys 2006: 65: 435.
27. Zhang Z, Bian H, Feng Q et al. Biodistribution and localization of iodine-131-labeled metuximab in patients with hepatocellular carcinoma. Cancer Biol Ther 2006: 5: 318.
28. Xu J, Shen ZY, Chen XG et al. A randomized controlled trial of Licartin for preventing hepatoma recurrence after liver transplantation. Hepatology 2007: 45: 269.
29. Alves RC, Alves D, Guz B et al. Advanced hepatocellular carcinoma. Review of targeted molecular drugs. Ann Hepatol 2011: 10: 21.
30. Gomez-Martin C, Bustamante J, Castroagudin JF et al. Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation. Liver Transpl 2012: 18: 45.
31. Weinmann A, Niederle IM, Koch S et al. Sorafenib for recurrence of hepatocellular carcinoma after liver transplantation. Dig Liver Dis 2012: 44: 432.
32. Yoon DH, Ryoo BY, Ryu MH et al. Sorafenib for recurrent hepatocellular carcinoma after liver transplantation. Jpn J Clin Oncol 2010: 40: 768.
33. Kim R, El-Gazzaz G, Tan A et al. Safety and feasibility of using sorafenib in recurrent hepatocellular carcinoma after orthotopic liver transplantation. Oncology 2010: 79: 62.
34. Tan WF, Qiu ZQ, Yu Y et al. Sorafenib extends the survival time of patients with multiple recurrences of hepatocellular carcinoma after liver transplantation. Acta Pharmacol Sin 2010: 31: 1643.
35. Saab S, McTigue M, Finn RS, Busuttil RW. Sorafenib as adjuvant therapy for high-risk hepatocellular carcinoma in liver transplant recipients: feasibility and efficacy. Exp Clin Transplant 2010: 8: 307.
36. Guba M, von Breitenbuch P, Steinbauer M et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002: 8: 128.
37. Kneteman NM, Oberholzer J, Al Saghier M et al. Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma. Liver Transpl 2004: 10: 1301.
38. Toso C, Meeberg GA, Bigam DL et al. De novo sirolimus-based immunosuppression after liver transplantation for hepatocellular carcinoma: long-term outcomes and side effects. Transplantation 2007: 83: 1162.
39. Zimmerman MA, Trotter JF, Wachs M et al. Sirolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma. Liver Transpl 2008: 14: 633.
40. Vivarelli M, Dazzi A, Zanello M et al. Effect of different immunosuppressive schedules on recurrence-free survival after liver transplantation for hepatocellular carcinoma. Transplantation 2010: 89: 227.
41. Toso C, Merani S, Bigam DL, Shapiro AM, Kneteman NM. Sirolimus-based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma. Hepatology 2010: 51: 1237.
42. Shetty K, Timmins K, Brensinger C et al. Liver transplantation for hepatocellular carcinoma validation of present selection criteria in predicting outcome. Liver Transpl 2004: 10: 911.
43. Shimoda M, Ghobrial RM, Carmody IC et al. Predictors of survival after liver transplantation for hepatocellular carcinoma associated with Hepatitis C. Liver Transpl 2004: 10: 1478.
44. Todo S, Furukawa H. Living donor liver transplantation for adult patients with hepatocellular carcinoma: experience in Japan. Ann Surg 2004: 240: 451.
45. Zavaglia C, De Carlis L, Alberti AB et al. Predictors of long-term survival after liver transplantation for hepatocellular carcinoma. Am J Gastroenterol 2005: 100: 2708.
46. Kim HS, Park JW, Jang JS et al. Prognostic values of alpha-fetoprotein and protein induced by vitamin K absence or antagonist-II in hepatitis B virus-related hepatocellular carcinoma: a prospective study. J Clin Gastroenterol 2009: 43: 482.
47. Ravaioli M, Grazi GL, Piscaglia F et al. Liver transplantation for hepatocellular carcinoma: results of down-staging in patients initially outside the Milan selection criteria. Am J Transplant 2008: 8: 2547.
48. Yao FY, Xiao L, Bass NM et al. Liver transplantation for hepatocellular carcinoma: validation of the UCSF-expanded criteria based on preoperative imaging. Am J Transplant 2007: 7: 2587.
49. Figueras J, Ibanez L, Ramos E et al. Selection criteria for liver transplantation in early-stage hepatocellular carcinoma with cirrhosis: results of a multicenter study. Liver Transpl 2001: 7: 877.
50. Pomfret EA, Washburn K, Wald C et al. Report of a national conference on liver allocation in patients with hepatocellular carcinoma in the United States. Liver Transpl 2010: 16: 262.
51. Jeng KS, Sheen IS, Tsai YC. Does the presence of circulating hepatocellular carcinoma cells indicate a risk of recurrence after resection? Am J Gastroenterol 2004: 99: 1503.
52. Morimoto O, Nagano H, Miyamoto A et al. Association between recurrence of hepatocellular carcinoma and alpha-fetoprotein messenger RNA levels in peripheral blood. Surg Today 1033: 2005: 35.
53. Marubashi S, Dono K, Nagano H et al. Detection of AFP mRNA-expressing cells in the peripheral blood for prediction of HCC recurrence after living donor liver transplantation. Transpl Int 2007: 20: 576.
54. Wang Y, Shen Z, Zhu Z, Han R, Huai M. Clinical values of AFP, GPC3 mRNA in peripheral blood for prediction of hepatocellular carcinoma recurrence following OLT: AFP, GPC3 mRNA for prediction of HCC. Hepat Mon 2011: 11: 195.
55. Koike Y, Shiratori Y, Sato S et al. Des-gamma-carboxy prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma: a prospective analysis of 227 patients. Cancer 2001: 91: 561.
56. Shirabe K, Itoh S, Yoshizumi T et al. The predictors of microvascular invasion in candidates for liver transplantation with hepatocellular carcinoma-with special reference to the serum levels of des-gamma-carboxy prothrombin. J Surg Oncol 2007: 95: 235.
57. Okuda H, Nakanishi T, Takatsu K et al. Serum levels of des-gamma-carboxy prothrombin measured using the revised enzyme immunoassay kit with increased sensitivity in relation to clinicopathologic features of solitary hepatocellular carcinoma. Cancer 2000: 88: 544.
58. Shimada M, Yonemura Y, Ijichi H et al. Living donor liver transplantation for hepatocellular carcinoma: a special reference to a preoperative des-gamma-carboxy prothrombin value. Transplant Proc 2005: 37: 1177.
59. Taketomi A, Sanefuji K, Soejima Y et al. Impact of des-gamma-carboxy prothrombin and tumor size on the recurrence of hepatocellular carcinoma after living donor liver transplantation. Transplantation 2009: 87: 531.
60. Yu L, Dai Z, Wang Z, Fan J, Zhou J. Prognostic indicators for tumor recurrence after liver transplantation in hepatocellular carcinoma and related molecular targeted therapy. Oncology 2011: 81(Suppl 1): 116.
61. Kozyraki R, Scoazec JY, Flejou JF et al. Expression of cadherins and alpha-catenin in primary epithelial tumors of the liver. Gastroenterology 1996: 110: 1137.
62. Dvorchik I, Schwartz M, Fiel MI, Finkelstein SD, Marsh JW. Fractional allelic imbalance could allow for the development of an equitable transplant selection policy for patients with hepatocellular carcinoma. Liver Transpl 2008: 14: 443.
63. Marsh JW, Finkelstein SD, Demetris AJ et al. Genotyping of hepatocellular carcinoma in liver transplant recipients adds predictive power for determining recurrence-free survival. Liver Transpl 2003: 9: 664.
64. Aucejo F, Kim R, Zein N et al. Vascular endothelial growth factor receptor 2 expression in non-tumorous cirrhotic liver is higher when hepatoma is beyond Milan criteria. Liver Transpl 2009: 15: 169.
65. Fiorentino M, Altimari A, Ravaioli M et al. Predictive value of biological markers for hepatocellular carcinoma patients treated with orthotopic liver transplantation. Clin Cancer Res 2004: 10: 1789.
66. Mazzaferro V, Llovet JM, Miceli R et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 2009: 10: 35.
67. Hemming AW, Cattral MS, Reed AI et al. Liver transplantation for hepatocellular carcinoma. Ann Surg 2001: 233: 652.
68. Salizzoni M, Romagnoli R, Lupo F et al. Microscopic vascular invasion detected by anti-CD34 immunohistochemistry as a predictor of recurrence of hepatocellular carcinoma after liver transplantation. Transplantation 2003: 76: 844.
69. Qin S, Bai Y, Ye S. Phase III study of oxaliplatin plus 5-fluorouracil/leucovorin (FOLFOX4) versus doxorubicin as palliative systemic chemotherapy in advanced HCC in Asian patients. J Clin Oncol 2010: 28: abstr4008.